Allergy and Immunology, Clinical & Laboratory Immunology · Hardeeville, SC
NPI
1568446581
Since 2005
Specialty
Allergy and Immunology, Clinical & Laboratory Immunology
Code 207KI0005X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
300 New River Parkway, Bldg 6 Suite 11
Hardeeville, SC, 29927
Phone (843) 208-6442
Groups this clinician bills Medicare through
Medicare paid, 2024
$324K
36,932 services
Medicare patients, 2024
689
Average age 75
Drug cost, 2024
$1.2M
1,236 prescriptions
Company payments, 2025
$606
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas C Beller was code 95165 (treatment - miscellaneous), 16,267 times for 369 patients. In total Thomas C Beller billed 36,932 services in 20 codes, and Medicare paid $324K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-05-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95165 Treatment - Miscellaneous | Office | 16,267 | 369 | $9.43 | $153K |
| 95004 Test - Miscellaneous | Office | 10,955 | 168 | $2.73 | $30K |
| 95117 Treatment - Miscellaneous | Office | 6,921 | 369 | $8.46 | $59K |
| 95024 Test - Miscellaneous | Office | 740 | 37 | $6.16 | $4,561 |
| 99213 Office E&M - Established | Office | 637 | 443 | $63.19 | $40K |
| 95115 Treatment - Miscellaneous | Office | 524 | 61 | $6.48 | $3,394 |
| 95170 Treatment - Miscellaneous | Office | 165 | 15 | $7.52 | $1,241 |
| 95145 Treatment - Miscellaneous | Office | 156 | 15 | $24.45 | $3,813 |
| 99204 Office E&M - New | Office | 144 | 144 | $117.64 | $17K |
| 95147 Treatment - Miscellaneous | Office | 82 | 11 | $43.83 | $3,594 |
| 99203 Office E&M - New | Office | 59 | 59 | $85.19 | $5,026 |
| 99214 Office E&M - Established | Office | 15 | 15 | $96.74 | $1,451 |
By year: 2022 $329K for 40,572 services; 2023 $338K for 40,399 services; 2024 $324K for 36,932 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas C Beller prescribed most often to Medicare patients was Gabapentin, with 359 prescriptions and refills. In total Thomas C Beller wrote 1,236 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 359 | 623 | 112 | $8,121 |
| Ipratropium Bromide Generic | 86 | 174 | 39 | $3,698 |
| Montelukast Sodium Generic | 83 | 219 | 23 | $1,325 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 77 | 110 | 32 | $2,515 |
| Prednisone Generic | 65 | 69 | 49 | $237 |
| Epinephrine Generic | 65 | 67 | 47 | $9,078 |
| Fluticasone Propionate Generic | 54 | 116 | 17 | $919 |
| Omeprazole Generic | 50 | 132 | 15 | $1,090 |
| Symbicort Budesonide/Formoterol Fumarate | 41 | 55 | Under 11 | $13K |
| Breo Ellipta Fluticasone/Vilanterol | 30 | 68 | Under 11 | $26K |
| Baclofen Generic | 23 | 40 | 18 | $515 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 23 | 41 | Under 11 | $3,744 |
| Cefdinir Generic | 22 | 22 | 16 | $378 |
| Levocetirizine Dihydrochloride Generic | 19 | 47 | Under 11 | $183 |
| Triamcinolone Acetonide Generic | 15 | 28 | Under 11 | $116 |
Brand drugs: 274 claims; generic drugs: 962 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas C Beller $606 ($606 in general payments such as food, travel and fees) from 8 companies. The largest payer was CSL Behring with $360.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 20 | $360 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $62.58 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $59.37 |
| GlaxoSmithKline, LLC. GSK | 2 | $40.11 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 1 | $27.57 |
| Pharming Healthcare, Inc. | 1 | $20.38 |
| Ionis Pharmaceuticals, Inc. IONS | 1 | $18.33 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $17.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.